Caribou Biosciences (CRBU) Operating Margin (2020 - 2026)
Caribou Biosciences (CRBU) reported Operating Margin of 1096.37% for Q1 2026, up 72739.0% year-over-year from N/an in Q1 2025, and down 51.86% quarter-over-quarter from 721.97% in Q4 2025.
Caribou Biosciences (CRBU) Operating Margin (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Operating Margin data on file, last reported at 1096.37% in Q1 2026.
- Operating Margin for Q1 2026 came in at 1096.37%, up 72739.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1175.68% (up 47311.0% YoY), and the FY2025 annual result was 1329.37%, up 33779.0% from the prior year.
- Operating Margin retreated to 1096.37% in Q1 2026 per CRBU's latest filing, from 721.97% in the prior quarter.
- Over five years, Operating Margin peaked at 61.84% in Q3 2023 and troughed at 1893.87% in Q1 2024.
- A 5-year average of 1155.58% and a median of 1052.33% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin tumbled 182739 bps in 2024, then surged 114972 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 828.22% in 2022, then dropped by 27 bps to 1052.33% in 2023, then tumbled by 78 bps to 1871.69% in 2024, then surged by 61 bps to 721.97% in 2025, then slumped by 52 bps to 1096.37% in 2026.
- Business Quant data shows CRBU's Operating Margin at 1096.37% in Q1 2026, 721.97% in Q4 2025, and 1337.58% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | -1,096.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,096.37% |
| Dec 31, 2025 | -721.97% |
| Sep 30, 2025 | -1,337.58% |
| Jun 30, 2025 | -1,783.95% |
| Mar 31, 2025 | -1,823.76% |
| Dec 31, 2024 | -1,871.69% |
| Sep 30, 2024 | -1,889.23% |
| Jun 30, 2024 | -1,255.80% |
| Mar 31, 2024 | -1,893.87% |
| Dec 31, 2023 | -1,052.33% |
| Sep 30, 2023 | -61.84% |
| Jun 30, 2023 | -875.31% |
| Mar 31, 2023 | -888.52% |
| Dec 31, 2022 | -828.22% |
| Sep 30, 2022 | -803.42% |
| Jun 30, 2022 | -678.22% |
| Mar 31, 2022 | -782.77% |
| Dec 31, 2021 | -797.38% |
| Sep 30, 2021 | -468.09% |
| Jun 30, 2021 | -1,081.57% |